Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 24, 2026, 5:46 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Long-term Follow-up Clear all
Enrolling by invitation Phase 3 Interventional

Follow-up Study of AAV-Mediated Gene Transfer (UX111; Previously Known as ABO-102) for MPS Type IIIA

NCT04360265
View directory record Official record
Conditions
Mucopolysaccharidosis IIIA, MPS IIIA, Sanfilippo Syndrome, Sanfilippo A
Interventions
No Investigational Product, Adjuvant Immunomodulatory (IM) Therapy
Other · Drug
Lead sponsor
Ultragenyx Pharmaceutical Inc
Industry
Eligibility
Not listed
Enrollment
41 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
1
States / cities
Columbus, Ohio
Source: ClinicalTrials.gov public record
Updated Jul 16, 2026 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Marathon and Enduron Polyethylene at Long-Term Follow-up

NCT02508428
View directory record Official record
Conditions
Osteoarthritis, Arthritis, Joint Diseases, Musculoskeletal Diseases, Rheumatic Diseases
Interventions
Hip Replacement with crosslinked Marathon polyethylene, Hip Replacement with noncrosslinked Enduron polyethylene
Device
Lead sponsor
Anderson Orthopaedic Research Institute
Other
Eligibility
Not listed
Enrollment
230 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
1999 – 2017
U.S. locations
1
States / cities
Alexandria, Virginia
Source: ClinicalTrials.gov public record
Updated Nov 30, 2020 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Phase 3 Interventional

Follow-up of the EPITOPE Study to Evaluate Long-term Efficacy and Safety of DBV712 in Young Children

NCT03859700
View directory record Official record
Conditions
Peanut Allergy
Interventions
DBV712 250 mcg
Biological
Lead sponsor
DBV Technologies
Industry
Eligibility
2 Years to 5 Years
Enrollment
304 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
26
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 22 more
Source: ClinicalTrials.gov public record
Updated Jun 5, 2025 · Synced Sep 24, 2026, 5:46 PM EDT
Enrolling by invitation Not applicable Interventional

Long-term Follow-up for Epidural Stimulation in SCI

NCT07042815
View directory record Official record
Conditions
SCI - Spinal Cord Injury
Interventions
Epidural Stimulation Programs
Device
Lead sponsor
Kessler Foundation
Other
Eligibility
18 Years and older
Enrollment
91 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
West Orange, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 28, 2025 · Synced Sep 24, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional

Open-Label, Long-Term Treatment Study, to Assess the Long-Term Safety and Tolerability and Efficacy of Neramexane in Patients With Subjective Tinnitus

NCT00827008
View directory record Official record
Conditions
Subjective Tinnitus
Interventions
Neramexane mesylate
Drug
Lead sponsor
Merz Pharmaceuticals GmbH
Industry
Eligibility
18 Years to 75 Years
Enrollment
821 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
31
States / cities
Tucson, Arizona • Burbank, California • Fresno, California + 27 more
Source: ClinicalTrials.gov public record
Updated Nov 27, 2012 · Synced Sep 24, 2026, 5:46 PM EDT
Completed No phase listed Observational

ADAGIO Follow Up Study: Evaluation of the Long-Term Effects of Rasagiline in Parkinson's Disease Subjects

NCT00936676
View directory record Official record
Conditions
Parkinson's Disease
Interventions
rasagiline mesylate
Drug
Lead sponsor
Teva Branded Pharmaceutical Products R&D, Inc.
Industry
Eligibility
Not listed
Enrollment
684 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
37
States / cities
Birmingham, Alabama • Tucson, Arizona • Irvine, California + 32 more
Source: ClinicalTrials.gov public record
Updated Apr 10, 2016 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Psilocybin on Behavior, Psychology and Brain Function in Long-term Meditators

NCT02145091
View directory record Official record
Conditions
Healthy
Interventions
Moderately-high dose of psilocybin, Moderately-low dose of psilocybin, Very-low dose of psilocybin, Placebo
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
25 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2019
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Dec 29, 2019 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Results available

Effect of Secukinumab on Radiographic Progression in Ankylosing Spondylitis as Compared to GP2017 (Adalimumab Biosimilar)

NCT03259074
View directory record Official record
Conditions
Ankylosing Spondylitis
Interventions
Placebo, GP2017 (adalimumab biosimilar), AIN457 150 mg
Biological
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
859 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
19
States / cities
Mesa, Arizona • Escondido, California • La Mesa, California + 16 more
Source: ClinicalTrials.gov public record
Updated Aug 20, 2023 · Synced Sep 24, 2026, 5:46 PM EDT
Recruiting Phase 1 Interventional

A Phase 1 Study of Vaccination With Dendritic Cell (DC)/Multiple Myeloma (MM) Fusions in Combination With Elranatamab in Relapsed or Refractory Multiple Myeloma

NCT06799026
View directory record Official record
Conditions
Multiple Myeloma, Relapse Multiple Myeloma, Refractory Multiple Myeloma
Interventions
Elranatamab, GM-CSF, DC/MM Fusion Vaccine
Drug · Biological
Lead sponsor
David Avigan
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 6, 2026 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Assessing Long-term CTN 0049 Outcomes, HCV Prevalence and Progression Along the HCV Care Continuum Among HIV/HCV Co-infected Substance Users in the U.S.

NCT02641158
View directory record Official record
Conditions
Hepatitis C, HIV, AIDS, Substance Use
Interventions
Control Group, Care Facilitation Group
Other · Behavioral
Lead sponsor
Columbia University
Other
Eligibility
18 Years and older
Enrollment
422 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2018
U.S. locations
11
States / cities
Birmingham, Alabama • Torrance, California • Miami, Florida + 8 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 24, 2026, 5:46 PM EDT
Not listed Phase 3 Interventional

A Study of AP-CD/LD in Fluctuating Parkinson's Disease Patients Who Completed IN 11 004

NCT02615873
View directory record Official record
Conditions
Parkinson's Disease
Interventions
Accordion Pill™ Carbidopa/Levodopa
Drug
Lead sponsor
Intec Pharma Ltd.
Industry
Eligibility
30 Years to 100 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
37
States / cities
Birmingham, Alabama • Phoenix, Arizona • Sun City, Arizona + 33 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2018 · Synced Sep 24, 2026, 5:46 PM EDT
Terminated Phase 2Phase 3 Interventional Results available

A Study to Test Long-term Treatment With Spesolimab in People With a Skin Condition Disease Called Hidradenitis Suppurativa (HS) Who Took Part in a Previous Study With Spesolimab

NCT06241573
View directory record Official record
Conditions
Hidradenitis Suppurativa (HS)
Interventions
Spesolimab, Placebo
Drug
Lead sponsor
Boehringer Ingelheim
Industry
Eligibility
18 Years and older
Enrollment
39 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
4
States / cities
Fountain Valley, California • Los Angeles, California • Sacramento, California + 1 more
Source: ClinicalTrials.gov public record
Updated Jun 16, 2026 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Long Term Immunity and Safety Following Vaccination With the JEV IC51 (IXIARO®, JESPECT®) in Pediatric Population In Non Endemic Countries. Uncontrolled, Ph3 FU-Study

NCT01246479
View directory record Official record
Conditions
Japanese Encephalitis
Interventions
Blood draw, IC51 has given in the parent study IC51-322
Procedure · Biological
Lead sponsor
Valneva Austria GmbH
Industry
Eligibility
9 Months to 20 Years
Enrollment
23 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2014
U.S. locations
1
States / cities
Tampa, Florida
Source: ClinicalTrials.gov public record
Updated Mar 17, 2020 · Synced Sep 24, 2026, 5:46 PM EDT
Recruiting Phase 2 Interventional

Safe Treatment for Emergency Presentation for Suicidal Ideation and Behavior in Youth

NCT05304065
View directory record Official record
Conditions
Suicide, Suicidal, Self-Harm
Interventions
SAFETY-A within usual ED Care, Combined SAFETY-A within usual ED Care + CLASP Therapeutic Follow-Up Contacts
Behavioral
Lead sponsor
University of California, Los Angeles
Other
Eligibility
13 Years to 24 Years
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
5
States / cities
Los Angeles, California • Sylmar, California • Durham, North Carolina + 2 more
Source: ClinicalTrials.gov public record
Updated Dec 30, 2025 · Synced Sep 24, 2026, 5:46 PM EDT
Not listed Not applicable Interventional

The Staying Safe Intervention

NCT03418636
View directory record Official record
Conditions
Hepatitis C, Opioid Use
Interventions
Staying Safe (Ssafe), Healthy Living
Behavioral
Lead sponsor
National Development and Research Institutes, Inc.
Other
Eligibility
18 Years to 29 Years
Enrollment
456 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated May 14, 2018 · Synced Sep 24, 2026, 5:46 PM EDT
Completed No phase listed Observational

LENS - Long-term Eltrombopag Observational Study

NCT00643929
View directory record Official record
Conditions
Purpura, Thrombocytopaenic, Idiopathic
Interventions
Eltrombopag
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
Not listed
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
5
States / cities
Tucson, Arizona • Washington D.C., District of Columbia • Detroit, Michigan + 2 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2017 · Synced Sep 24, 2026, 5:46 PM EDT
Terminated Phase 3 Interventional Results available

BMN 701 Phase 3 in rhGAA Exposed Subjects With Late Onset Pompe Disease (INSPIRE Study)

NCT01924845
View directory record Official record
Conditions
Late-onset Pompe Disease
Interventions
BMN 701
Drug
Lead sponsor
BioMarin Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
8
States / cities
Phoenix, Arizona • Orange, California • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 24, 2026, 5:46 PM EDT
No Longer Available No phase listed Expanded access

Expanded Access Protocol - Blinatumomab in Pediatric & Adolescent Subjects With Relapsed/Refractory B-precursor ALL

NCT02187354
View directory record Official record
Conditions
Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia
Interventions
Blinatumomab, Extension of LTFU as per ProtocolAmendment7 7Jun18
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
0 Years to 17 Years
U.S. locations
4
States / cities
Aurora, Colorado • Cincinnati, Ohio • Memphis, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated May 12, 2024 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional

Standard Follow-up Compared With Extended Follow-up in Treating Patients Who Have Undergone Stem Cell Transplantation for Cancer

NCT00049465
View directory record Official record
Conditions
Cancer
Interventions
fatigue assessment and management, management of therapy complications, psychosocial assessment and care
Procedure
Lead sponsor
Fred Hutchinson Cancer Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
9
States / cities
Stanford, California • Denver, Colorado • Gainesville, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2010 · Synced Sep 24, 2026, 5:46 PM EDT
Active, not recruiting Not applicable Interventional

Examinations of Tissue From Ablated Malignant Liver Metastases as Predictors of Outcome

NCT01494324
View directory record Official record
Conditions
Liver Cancer
Interventions
CT guided percutaneous ablation
Other
Lead sponsor
Memorial Sloan Kettering Cancer Center
Other
Eligibility
18 Years and older
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2026
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jan 1, 2026 · Synced Sep 24, 2026, 5:46 PM EDT
Active, not recruiting No phase listed Observational

Long-term Assessment of the Safety and Performance of the NuVasive Simplify Disc

NCT05258435
View directory record Official record
Conditions
Cervical Disc Disease, Degenerative Disc Disease
Interventions
NuVasive Simplify Cervical Artificial Disc
Device
Lead sponsor
NuVasive
Industry
Eligibility
Not listed
Enrollment
131 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
10
States / cities
Orange, California • Santa Monica, California • Thornton, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2025 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Behavioral Memory Modulation in Nicotine Addiction

NCT03744559
View directory record Official record
Conditions
Nicotine Use Disorder
Interventions
Retrieval Extinction Training (RET), Control Retrieval Extinction Training (RET)
Behavioral
Lead sponsor
Medical University of South Carolina
Other
Eligibility
25 Years to 65 Years
Enrollment
191 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2023
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

An Open-label Extension Study to Evaluate the Long-term Safety and Tolerability of LOU064 in Subjects With CSU

NCT04109313
View directory record Official record
Conditions
Chronic Spontaneous Urticaria
Interventions
LOU064
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 99 Years
Enrollment
229 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
10
States / cities
Litchfield Park, Arizona • Little Rock, Arkansas • Mission Viejo, California + 7 more
Source: ClinicalTrials.gov public record
Updated Jun 19, 2024 · Synced Sep 24, 2026, 5:46 PM EDT
Completed Phase 2 Interventional Results available

Long Term Study of Canakinumab (ACZ885) in Patients With Gout

NCT00927810
View directory record Official record
Conditions
Gouty Arthritis
Interventions
Canakinumab
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 80 Years
Enrollment
341 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 1, 2021 · Synced Sep 24, 2026, 5:46 PM EDT